Alto Neuroscience ANRO Other comprehensive income (loss)
Other comprehensive income (loss) at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTax.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's other comprehensive income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's other comprehensive income (loss)?
- Alto Neuroscience (ANRO) reported other comprehensive income (loss) of -$26.25M in Q1 2026.
- How has Alto Neuroscience's other comprehensive income (loss) changed year-over-year?
- Alto Neuroscience's other comprehensive income (loss) decreased by 74.3% year-over-year, from -$15.05M to -$26.25M.
- What is the long-term trend for Alto Neuroscience's other comprehensive income (loss)?
- Over 2 years (2023 to 2025), Alto Neuroscience's other comprehensive income (loss) has grown at a 31.8% compound annual growth rate (CAGR), from -$36.34M to -$63.12M.
- What does other comprehensive income (loss) mean?
- This metric represents revenues, expenses, gains, and losses that are excluded from net income under accounting standards but are recognized as changes in equity. It typically includes items such as unrealized gains or losses on available-for-sale securities or foreign currency translation adjustments. Monitoring this provides a more comprehensive view of the company's total financial performance beyond standard operating activities.